Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.
Stocks in play: Knight Therapeutics Inc.
Has entered into an exclusive license agreement with Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, granting Knight the rights to seek regulatory approval and commercialize Qelbree® in Canada. Qelbree® is an extended-release formulation of viloxazine, a multimodal serotonergic and norepinephrine modulating agent (SNMA), a nonstimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD). Financial terms of the agreement were not disclosed. Knight Therapeutics Inc. shares T.GUD are trading unchanged at $5.15.
